Astrazeneca PLC SEC filings AZN
Astrazeneca PLC has 1,001 filings in SEC EDGAR's recent list, going back to Jun 19, 2019. Its latest annual report, Form 20-F, was filed on Feb 24, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Nov 2, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 4 | Insider transaction | Oct 8, 2026 | Oct 6, 2026 |
| 4 | Insider transaction | Sep 11, 2026 | Aug 8, 2026 |
| 4 | Insider transaction | Aug 7, 2026 | Aug 6, 2026 |
| 4 | Insider transaction | Jul 8, 2026 | Jul 6, 2026 |
| 4 | Insider transaction | Jun 16, 2026 | Jun 8, 2026 |
| 4 | Insider transaction | May 22, 2026 | May 20, 2026 |
| 4 | Insider transaction | May 8, 2026 | Apr 7, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Apr 28, 2026 | — |
| 3 | Initial insider ownership | Mar 19, 2026 | Mar 18, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 6, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Feb 6, 2026 | — |
| 144 | Notice of proposed sale | Nov 12, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Apr 23, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Apr 10, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jan 24, 2025 | — |
| SC 13G | Ownership over 5% (passive) | Oct 28, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Oct 11, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 12, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Jan 24, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Nov 16, 2023 | — |
| 144 | Notice of proposed sale | Nov 13, 2023 | — |
| SC 13D | Ownership over 5% (active) | Nov 9, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 10, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 10, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Jan 24, 2023 | — |
| SC 13G | Ownership over 5% (passive) | Jul 8, 2022 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 7, 2022 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 4, 2022 | — |
| SC 13G | Ownership over 5% (passive) | Jul 27, 2021 | — |
| SC 13G | Ownership over 5% (passive) | Apr 8, 2021 | — |
| 4 | Insider transaction | Mar 16, 2021 | Mar 15, 2021 |
| SC 13G | Ownership over 5% (passive) | Feb 10, 2021 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 10, 2021 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 3, 2021 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Jan 29, 2021 | — |
| 4 | Insider transaction | Feb 7, 2020 | Dec 19, 2019 |
| 3 | Initial insider ownership | Feb 7, 2020 | Dec 19, 2019 |
| SC 13D | Ownership over 5% (active) | Feb 7, 2020 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 5, 2020 | — |
| SC 13G | Ownership over 5% (passive) | Jan 30, 2020 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Jan 27, 2020 | — |
| SC 13D | Ownership over 5% (active) | Oct 25, 2019 | — |
| 4 | Insider transaction | Oct 9, 2019 | Oct 7, 2019 |
| 3/A | Form 3/a submission | Oct 9, 2019 | Oct 2, 2019 |
| 3 | Initial insider ownership | Oct 2, 2019 | Oct 2, 2019 |
Showing 45 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AZN (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- Cambridge
- SEC filer status
- Large accelerated filer
- SEC CIK
- 901832
- Former names
- ZENECA GROUP PLC (until Feb 5, 1999)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
- Pfizer Inc PFE
Source: SEC EDGAR filings. This is company-reported data, not investment advice.